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Abstract
Primary malignant melanoma of the esophagus is an uncommon tumor, with approximately 300 cases having been
reported thus far. The purpose of this study was to describe a case of a 60 year-old man with a 10 month history of
progressive dysphagia and thoracic pain, the investigations of which led to a diagnosis of primary malignant
melanoma of the esophagus. The patient underwent a transhiatal esophagectomy with subcarinal
lymphadenectomy, and isoperistaltic gastric tube replacement of the esophagus. Nine months after surgery, he
developed ischemic colitis, and metastasis in the mesentery was diagnosed. His disease progressed and he died
one year after the esophagectomy. A review of the literature was performed.
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Background
Melanoma is more frequently found in sun-exposed
areas; however it can appear in other sites including the
mucosal surfaces [1]. Primary malignant melanoma of
the esophagus is more common in the elderly and the
diagnosis is usually made in advanced stages of the
disease; it has a worse prognosis than cutaneous
melanoma.
Melanocytes are present in small amounts in the squa-
mous epithelium or basal membrane of the esophagus,
and can be the precursors of melanocytosis and primary
malignant melanoma.
Primary malignant melanoma of the esophagus is
characterized by aggressive local invasion and mul-
tiple and early metastasis. Despite the availability of
multimodal therapies such as radical surgery, chemo-
therapy, radiotherapy, and immunotherapy, the prog-
nosis is still poor [2-4]. More recently, the prognosis
seems to have improved, and studies suggest that this
may be associated with tumor early detection.
Case presentation
A 60 year-old man was hospitalized with a 10 month
history of progressive dysphagia and chest pain. He was
a former smoker for 50 years (40 cigarettes/day). He de-
nied personal or family history of cancer. On physical
examination, no skin, ocular lesions, or palpable lymph
nodes were detected.
Upper digestive endoscopy showed an 8.0 cm polypoid
tumor, located in the lower third of the esophagus, about
30 cm from the upper dental arch, which occupied 80%
of the esophageal lumen (Figure 1). Biopsies with immu-
nohistochemical studies were compatible with malignant
melanoma: AE-1/AE-3 negative, P63 protein negative, S-
100 protein positive focal, melanA positive and HMB-45
positive (Figures 2, 3, 4, 5 and 6).
Computed tomography (CT) was performed for clin-
ical staging which showed a 4.7 × 3.8 × 2.1 cm tumor in
the lower third of the esophagus (Figure 7). There were
peritracheal lymph nodes measuring 1.4 × 0.9 cm near
the esophagogastric junction. Positron emission tomog-
raphy (PET-CT) showed uptake of fluorine-18-2-fluoro-
2-deoxy-D-glucose (FDG) only in the esophageal tumor,
with no evidence of lymph node or distant metastatic
disease (Figures 8).
The patient underwent transhiatal esophagectomy with
subcarinal lymphadenectomy, and isoperistaltic gastric
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tube replacement of the esophagus. During the oper-
ation, no evidence of metastatic disease was observed.
Anatomopathologic examination confirmed malignant
melanoma of nodular type, measuring 8.5 cm, with infil-
tration of the muscular layer up to 3.3 cm. There was
no lymphatic or venous invasion. There was evidence of
perineural invasion, desmoplasmin mild peritumoral,
mild intra and peritumoral lymphocytic response, ulcer-
ation, and the rate of four mitoses per 10 fields. The
margins were free from malignant involvement. There
were 26 dissected lymph nodes (11 in the esophageal
adventitia, 1 at the esophagogastric junction and 14 at
the lesser curvature and celiac trunk) without evidence
of malignancy.
The patient’s postoperative recovery was uneventful.
Five months after the surgery, a CT scan suggested
lymph node recurrences in the left external iliac
chain, subcarinal and perigastric nodes. A fine-needle
endoscopic-ultrasound-guided aspiration confirmed the
recurrence. The molecular analysis for mutation of c-KIT
was negative. Afterwards, chemotherapy with dacarbazine
was started.
Nine months after surgical treatment and the second
cycle of chemotherapy, he was admitted to hospital due to
abdominal distension and pain. The abdominal CT showed
pneumoperitoneum (Figure 9) without evidence of iodine
outside the intestinal lumen. The main features were of in-
testinal gaseous distension of the colon (Figure 9) and the
presence of free fluid in the abdominal cavity. There was a
hypodense nodular lesion next to the jejunum in the left
flank measuring 2.5 × 1.8 cm that appeared to be metastatic
disease (Figure 10).
Also observed were left external iliac chain lymph-
adenopathy, bilateral pleural effusions and a poorly
Figure 1 Polypoid tumor measuring 8.0 cm, located in the lower third of the esophagus, which occupied 80% of the
esophageal lumen.
Figure 2 Immunohistochemical staining negative for
AE-1/AE-3 (X100).
Figure 3 Immunohistochemical staining negative for P63
protein (X100).
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characterized mediastinal mass. An exploratory laparot-
omy was performed which diagnosed an ischemic colitis,
and a lobulated pigmented lesion measuring 2.0 cm,
located 40 cm from the Treitz’s angle. Subtotal colectomy
and terminal ileostomy were performed. The patient’s
recovery was uneventful and he was started on therapy
with ipilimumab. However, his disease progressed and he
died one year after the first surgical intervention.
Discussion
The first case of primary malignant melanoma of the
esophagus was reported by Baur in 1906. It is believed
that in common with those occurring in the skin, mela-
nocytes present in the esophageal epithelium are derived
from neural crest tissue from where they migrate during
embryogenesis [5,6].
It is a rare disease with estimated frequency of 0.1 to
0.2% of all malignancies in the esophagus, with a total of
337 reported cases up to the year 2011 [7,8].
Up until now, no risk group has been identified. Stud-
ies have been showing an average age at diagnosis of
60.5 years, and a male to female prevalence ratio of 2:1
[2], the present case providing an example of this male
preponderance. The most common locations are in the
lower and middle thirds of the esophagus, as reported in
more than 90% of cases in some series. This is due to
the fact that there is a greater concentration of melano-
cytes in this location [6].
Esophageal melanocytosis is a benign condition in
which there is proliferation of melanocytes in the basal
layer, with consequent increase in the amount of mel-
anin in the mucosa. The immunohistochemistry is posi-
tive for melanocytic markers, such as S-100, melanA
and HMB-45. Melanocytosis occurs in 25 to 30% of pa-
tients with primary malignant melanoma of the esopha-
gus and in 7.7% of subjects without esophageal disease,
suggesting this as a predisposing factor for this disease [2].
The most common symptoms of primary malignant
melanoma of the esophagus are dysphagia and epigas-
tric pain which are present in 70% of patients, as well as
in our case. The occurrence of hematemesis or melena
is unusual.
The diagnosis is often difficult, since the symptoms
are nonspecific and there is often a low suspicion level
due to the rarity of the disease. This is especially so in
the absence of evident melanin granules as diagnostic er-
rors may occur because the lesions are not considered as
showing clearly differentiated carcinoma. In addition,
the differential diagnosis between primary and meta-
static melanoma of the esophagus is difficult and some
published studies suggest some criteria for differenti-
ation between primary and metastatic disease [9].
Although radiological studies such as esophagography,
computed tomography and magnetic resonance imaging
can identify and locate the tumor, the diagnosis can only
be established by upper digestive endoscopy with biopsy
and immunohistochemical studies [10]. During endo-
scopic examination, primary esophageal melanoma usu-
ally appears as a pedunculated polypoid and pigmented
tumor, covered by normal mucosa and not ulcerated. Its
color varies depending on the amount of melanin, which
can be absent (amelanotic melanoma). The presence of
Figure 4 Immunohistochemical staining positive focal for S-100
protein (X400).
Figure 5 Immunohistochemical staining positive for melanA protein (5A. X100 and 5B. X200).
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other lesions in the esophageal wall, called satellite injur-
ies, indicates intramural metastasis of the melanoma. In
addition to the presence of melanocytosis, the diagnosis
of melanoma in situ can support the diagnosis of the
primary disease.
Histological findings consist of pigmented cells that
grow wildly and show irregular, fusiform or similar struc-
tures to the epithelioid cells. In nearly 20 to 50% of the
cases, melanin granules are not detected in the cytoplasm.
In these cases, immunohistochemical positive study for S-
100 protein, HMB-45, neuron-specific enolase and nega-
tive for cytokeratin and CEA confirm the diagnosis of mel-
anoma and exclude carcinoma.
In a review of 10 cases, in order to differentiate between
primary and metastatic lesions, of which five had primary
malignant melanoma of the esophagus, and the other five,
metastatic melanoma to the esophagus, it was observed
that in 100% of the cases of metastatic disease, there was a
prior history of cutaneous malignant melanoma which
was not present in any of the cases in the other group.
Most patients with metastatic disease in the esophagus
had metastases in other sites, suggesting that metastasis to
the esophagus occurs only in a very advanced stage of the
disease. The criteria established by this study indicate that
primary melanomatous diseases of the esophagus were:
the presence of melanoma in situ, the presence of a radial
growth phase, melanocytosis and a mixture of histology of
epithelioid and fusiform cells, in the absence of a history
of melanoma at another site [9].
The most frequent site of metastasis is the regional
lymph nodes (40 to 80%) such as the periesophageal chain
followed by distant lymph nodes and organs including the
liver (31%), lungs (18%) and brain (13%). Autopsies of 45
patients showed evidence of metastasis in 78% [11].
The clinical staging can be performed by endoscopic
ultrasound, especially in non-advanced tumors, CT, and/
or magnetic resonance imaging, and PET.
The seventh edition of the TNM, published by the
American Joint Comission on Cancer in 2010, intro-
duced a new classification for melanoma of the upper
aerodigestive tract. In this classification T1, T2 and
stages 1 and 2 were left out due to the aggressive nature
of mucosal melanomas (Tables 1 and 2) [12]. This clas-
sification is not widely utilized in the literature and it
was mentioned only by Langer et al. [13]. Other authors
have used the TNM classification similarly for staging of
squamous cell carcinoma and adenocarcinoma.
This classification differentiates adequately the prognosis,
T3 having a considerably better prognosis than T4, and
emphasizes the aggressive nature of melanoma compared
to adenocarcinoma and squamous cell carcinoma. The rar-
ity of primary malignant melanoma of the esophagus pre-
vents randomized studies to support therapeutic decisions
being carried out. In the absence of prospective random-
ized controlled studies, the review of case reports points
out that total, almost total, or partial esophagectomy, with
or without gastrectomy is the preferred surgical treatment
in resectable disease patients [3,4,14,15]. Surgical resection
is the only modality treatment that influences survival.
Esophagectomy with three-field lymph node dissection
(periesophageal, mediastinal and celiac trunk) is the
treatment of choice when possible [8]. Surgical margins
Figure 6 Immunohistochemical staining positive for HMB-45 protein (6A. X100 and 6B. X200).
Figure 7 CT scan shows a bulky tumor in the lower third of the
esophagus (arrow).
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must be broader than in other esophageal malignancies, as
satellite lesions are frequent. However this procedure is
associated with high postoperative morbidity and mortal-
ity, and it is difficult to determine the cost benefit, since
most patients die from disease recurrence in a short
period of time even after curative resection, as occurred in
this present case [16]. As reported by Adili and Mönig,
the resection of isolated metastases even in different
locations, can be beneficial for long-term survival [6].
Mukaya et al. reported a case of successful surgical
treatment for tumor recurrence. In a literature review
conducted by the authors (another case), it has been
shown that surgical resection, when possible, is the
treatment of choice in cases of tumor recurrence [17].
Endoscopic mucosal resection can be performed for
tumors restricted to the mucosal layer. It is mainly indi-
cated for patients with associated diseases which discour-
age surgery. It should not be performed for tumors that
invade the submucosal layer or in the presence of meta-
static lymph nodes. The degree of tumor invasion and
metastatic lymph node involvement can be effectively
evaluated using endoscopic ultrasound [17]. A careful
histological analysis of the resected segment, ensuring
free margins and a rigorous post-procedure follow-up are
necessary. Endoscopic laser ablation can be used as
palliative treatment in locally advanced tumors.
Other therapeutic modalities such as radiotherapy,
chemotherapy and immunotherapy have controversial
efficacy. Radiation therapy is indicated for obstructive
unresectable tumors as a palliative treatment. Endoscopic
metallic stents can also be used for this purpose.
Chemotherapy usually includes dacarbazine, nimustine,
vincristine and cisplatin. Dacarbazine confirmed its efficacy
Figure 8 PET-CT demonstrates FDG uptake only in the esophageal lesion, with no evidence of lymph node or distant metastatic disease.
a) front view; b) lateral view; c) PET-CT transversal section showing the esophageal tumor uptake.
Figure 9 Pneumoperitoneum (arrow 1), gaseous distension of
the colon (arrow 2) and the presence of free fluid in the
abdominal cavity is shown in the abdominal CT.
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for cutaneous malignant melanoma. A randomized con-
trolled trial which compared the Dartmouth regimen
(dacarbazine, cisplatin, bischloroethylnitrosourea and tam-
oxifen), CVD (cisplatin, vindesine and dacarbazine) and
BOLD (bleomycin, vincristine, dacarbazine and loumostine)
with only dacarbazine, for patients with metastatic melan-
oma, did not show survival improvement for these associa-
tions when compared with isolated dacarbazine [2].
Immunotherapy has evolved considerably. Currently,
new therapeutic modalities have appeared in addition to
interferon, as vaccines for activating the dendritic cells as
well the passive immunotherapy as lymphokine-activating
killer cell and monoclonal therapy directed to specific
antigens of the melanoma.
Studies with various agents were performed but no gold
standard systemic therapy has been found. None of these
agents showed increased overall survival, although they
have shown some beneficial effect. It is difficult to assess
the value of these studies for primary malignant melan-
oma of the esophagus because these tumors are rare; most
of what is applied is the extrapolation of results from stud-
ies of melanomas of other sites or from studies providing
low grades of evidence.
Molecular analysis could identify targets as an option
for additional specific therapy in tumors of a high
degree of malignancy. In a series of ten patients with
primary malignant melanoma of the esophagus studied
by Langer et al., the mutation of c-KIT, among others
was detected in two by molecular analysis, and in all by
immunohistochemistry [13]. The detection of this mu-
tation by molecular analysis is relevant, since its pres-
ence, although rare, in primary malignant melanoma of
the esophagus, may be related to response to therapy
with tyrosine kinase inhibitor. In the reported case, the
research for molecular analysis of mutation of c-Kit
was negative.
The prognosis of malignant melanoma of the esopha-
gus is dreadful [10,16], because in addition to having a
highly aggressive biological behavior, most patients are
diagnosed late, with the disease at an advanced stage
[15]. The improvement in survival of these patients de-
pends on early diagnosis. In a literature review, Bisceglia
et al. studied the rate of long-term survival adjusted to
the T stage. They found that all patients who survived 36
months or more had stage T1, except for one whose sta-
ging of the tumor was pT2pN0, therefore, emphasizing
the importance of early diagnosis. Sabanathan, in a series
of 139 patients, reported an average survival rate of 10
months and a five-year survival after surgical treatment
of 4.2% [18]. More recently, Volpin et al. published a
study with 25 patients, in whom the five-year survival
was 37%, and this finding was mainly attributed to early
diagnosis.
Conclusions
Malignant melanoma of the esophagus is a rare and ag-
gressive disease. Its diagnosis is difficult and usually
made late, in the advanced stages of the disease, provid-
ing a poor prognosis with low long-term survival rates
even after appropriate treatment. A better survival rate
can be achieved if the diagnosis is made early. The treat-
ment of choice is surgical resection whenever possible,
even in cases of recurrent or metastatic disease. Radio-
therapy and chemotherapy have not shown benefits in
survival rates to date. Other forms of therapy are being
studied, but still no benefits in survival rates have been
demonstrated. Currently, studies with a high level of evi-
dence are not feasible for implementation, due to the
rarity of the disease.
Consent
The patient consented to the study and publication of
this case report and images. A written consent is avail-
able for review.
Table 1 T classification for melanoma of the upper
aerodigestive tract
T3 Epithelium (mucosal disease)
T4a Deep soft tissue, cartilage, bone or overlying skin
T4b Brain, dura, skull base, lower cranial nerves, masticator space,
carotid artery, prevertebral space, mediastinal structures, cartilage,
skeletal muscle or bone.
AJCC [12].
Table 2 TNM classification
Stage III T3 N0 M0
Stage IVA T4a N0 M0
T3-T4a N1 M0
Stage IVB T4b Any N M0
Stage IVC Any T Any N M1
AJCC [12].
Figure 10 Abdominal CT shows hypodense nodular lesion next
to the jejunum in the left flank, measuring 2.5 × 1.8 cm.
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